MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and ...

Explore how lived patient experiences are transforming clinical trials and corporate leadership in the life sciences sector.

An update to the guidelines for urticaria management was published, involving collaboration from various international ...

Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafterCash and cash ...

Hello, and welcome to Wave Life Sciences Positive Interim Phase I Clinical Data from INLIGHT Trial of WVE-007 for Obesity Call. [Operator Instructions] Also, as a reminder, this conference is being ...

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs ...

Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's ...

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON, N.J.

Biologics represent a breakthrough in the management of airway diseases, offering precision treatments that target specific immune pathways. This special issue, Biologics for Airway Diseases: From ...

Many managerial problems are not optimization issues – they center on ethics and judgment and cannot be adjudicated by ...